Bibliographies thématiques / Acido Gadoxetico

Littérature scientifique sur le sujet « Acido Gadoxetico »

Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Acido Gadoxetico ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Acido Gadoxetico"

1

Koh, Dow-Mu, Ahmed Ba-Ssalamah, Giuseppe Brancatelli, Ghaneh Fananapazir, M. Isabel Fiel, Satoshi Goshima, Sheng-Hong Ju et al. « Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging : applications of gadoxetic acid-enhanced imaging ». European Radiology 31, no 8 (1 février 2021) : 5615–28. http://dx.doi.org/10.1007/s00330-020-07637-4.

Texte intégral
Résumé :
Abstract Objectives The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid–enhanced imaging. Methods As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid–enhanced MRI in primary liver cancer and metastatic liver disease. Results and conclusions Gadoxetic acid–enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid–enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid–enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers. Key Points • Gadoxetic acid–enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy. • Gadoxetic acid–enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies. • Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid–enhanced MRI for the assessment of liver and biliary function is under active investigation.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Tsuboyama, Takahiro, Gregor Jost, Tonsok Kim, Masatoshi Hori, Hiromitsu Onishi, Hubertus Pietsch et Noriyuki Tomiyama. « Experimental studies on artifacts and tumor enhancement on gadoxetic acid-enhanced arterial phase liver MRI in a rabbit VX2 tumor model ». Acta Radiologica 59, no 9 (13 décembre 2017) : 1029–37. http://dx.doi.org/10.1177/0284185117747134.

Texte intégral
Résumé :
Background Rapid injection of gadoxetic acid is reported to produce more frequent artifacts and lower vascular enhancement on arterial phase liver magnetic resonance imaging (MRI). However, its effect on tumor enhancement and the mechanism of the artifacts remain unclear. Purpose To evaluate the effect of rapid injection of gadoxetic acid on artifacts and tumor enhancement during arterial phase liver MRI, and on arterial blood gases (ABGs) which may explain the cause of the artifacts. Material and Methods ABG analysis was performed in 13 free-breathing rabbits after rapid injection (1 mL/s; injection time = 0.6–0.8 s) of gadoxetic acid (0.025 mmol/kg). Dynamic liver MRI was performed in six anesthetized rabbits with VX2 tumors under a ventilation stoppage after rapid and slow injection (0.25 mL/s; injection time = 2.4–3.2 s) of gadoxetic acid. Artifacts and signal enhancement on arterial phase imaging were compared with those obtained after rapid injection of gadopentetic acid (Gd-DTPA, 0.1 mmol/kg) using a Friedman test or Kruskal–Wallis test. Results ABG analysis did not find any significant changes. Artifacts were not related to injection protocols ( P = 0.95). Aortic enhancement with slow injection of gadoxetic acid was significantly higher than that with rapid injection ( P < 0.05), and was comparable to that with Gd-DTPA injection. Tumor enhancement obtained with gadoxetic acid was not significantly different between rapid and slow injection, and was significantly lower than that with Gd-DTPA injection ( P < 0.05). Conclusion Rapid injection of gadoxetic acid did not affect ABGs and may not be the cause of the artifacts. It lowered vascular enhancement but not arterial tumor enhancement.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Seidensticker, Max, Ingo G. Steffen, Irene Bargellini, Thomas Berg, Alberto Benito, Bernhard Gebauer, Roberto Iezzi et al. « Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort ». Current Oncology 29, no 2 (27 janvier 2022) : 565–77. http://dx.doi.org/10.3390/curroncol29020051.

Texte intégral
Résumé :
The value of gadoxetic acid in the diagnosis of hepatocellular carcinoma (HCC), based on perfusion criteria, is under dispute. This post-hoc analysis of the prospective, phase II, randomized, controlled SORAMIC study compared the accuracy of gadoxetic acid-enhanced dynamic magnetic resonance imaging (MRI) (arterial, portovenous, and venous phase only) versus contrast-enhanced computed tomography (CT) for stratifying patients with HCC to curative ablation or palliative treatment. Two reader groups (radiologists, R1 and R2) performed blind reads of CT and gadoxetic acid-enhanced MRI (contrast dynamics only). A truth panel, with access to clinical and imaging follow-up data, served as reference. Primary endpoint was non-inferiority (margin: 5% points) of MRI vs. CT (lower 95% confidence interval [CI] > 0.75) in a first step and superiority (complete 95% CI > 1) in a second step. The intent-to-treat population comprised 538 patients. Accuracy of treatment decisions was 73.4% and 70.8% for CT (R1 and R2, respectively) and 75.1% and 70.3% for gadoxetic acid-enhanced dynamic MRI. Non-inferiority but not superiority of gadoxetic acid-enhanced dynamic MRI versus CT was demonstrated (odds ratio 1.01; CI 0.97–1.05). Despite a theoretical disadvantage in wash-out depiction, gadoxetic acid-enhanced dynamic MRI is non-inferior to CT in accuracy of treatment decisions for curative ablation versus palliative strategies. This outcome was not subject to the use of additional MR standard sequences.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Bai, Chongxin, Kewen Liu, Shi Chen, Zhao Li, Weida Xie, Qingjia Bao et Chaoyang Liu. « Dual-domain unsupervised network for removing motion artifact related to Gadoxetic acid-enhanced MRI ». Journal of Physics : Conference Series 2258, no 1 (1 avril 2022) : 012037. http://dx.doi.org/10.1088/1742-6596/2258/1/012037.

Texte intégral
Résumé :
Abstract The transient severe motion may cause severe image degradation during gadoxetic acid-enhanced arterial phase imaging. This work proposes a new dual-domain unsupervised motion artifacts disentanglement network for motion correction related to gadoxetic acid-enhanced MRI. We assume that motion-free images and motion-corrupted images belong to the different domains, then the motion correction is converted to the image-to-image translation problem. The image-to-image translation within the same domain is designed to constrain autoencoders to learn the feature representation. And the cross-domain translation explores the cycle consistency in the absence of paired images. Experimental results demonstrate that our method can effectively reduce artifacts in the gadoxetic acid-enhanced images.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Kаrmаzаnovsky, G. G., et A. A. Volobueva. « Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoxetic Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma ». Journal of radiology and nuclear medicine 102, no 5 (17 novembre 2021) : 284–95. http://dx.doi.org/10.20862/0042-4676-2021-102-5-284-295.

Texte intégral
Résumé :
Objective: to evaluate pharmacoeconomic advantages of the application of magnetic resonance imaging (MRI) with hepatobiliary-specific contrast agent – gadoxetic acid in addition to contrast-enhanced computed tomography (CT) in the diagnosis of hepatocellular carcinoma (HCC).Material and methods. We performed the modeling and obtained the results of the pharmacoeconomic study: effectiveness analysis, cost analysis, and cost-effectiveness analysis. The cost analysis included only direct medical costs (the cost of contrast-enhanced CT, gadolinium-based contrast agent (GBCA) for MRI, and therapy per a patient with verified HCC diagnosis after diagnostic procedures). The financing was performed from the Compulsary Health Insurance Fund. The calculations were made per 1 patient.Results. The effectiveness analysis showed that the diagnostic scheme CT + MRI with gadoxetic acid was the most effective complex for the diagnosis of HCC because its application provided 50% of patients with 5-year overall survival (4.8 years), which was significantly higher than in patients who were diagnosed HCC with CT + MRI with extracellular GBCA (2.3 years) or CT (3.7 years). The cost-effectiveness analysis showed that the diagnostic scheme with gadoxetic acid was dominant because each disability-adjusted life year required fewer costs (14 862 rubles) in comparison with CT + MRI with extracellular GBCA (25 293 rubles) or CT (46 540 rubles). According to the results of the incremental cost-effectiveness ratio analysis, the application of the diagnostic complex with gadoxetic acid was characterized by the lowest rate of additional costs per 1 disability-adjusted life year.Conclusion. The pharmacoeconomic study showed that the application of MRI with a hepatospecific contrasting agent – gadoxetic acid in addition to contrast-enhanced CT was an effective and economically beneficial method of early HCC diagnosis.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Kim, Ka Eun, Dong Hyun Sinn, Moon Seok Choi et Honsoul Kim. « Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment ». PLOS ONE 17, no 1 (27 janvier 2022) : e0262750. http://dx.doi.org/10.1371/journal.pone.0262750.

Texte intégral
Résumé :
Purpose Hepatocellular carcinoma (HCC) patients usually achieve a complete response after treatment. This study was aimed to assess the clinical outcome of HCC patients who had achieved a complete response but later presented with elevated tumor marker levels without an identifiable recurrent tumor on gadoxetic acid-enhanced magnetic resonance imaging (MRI). Methods We retrospectively reviewed the clinical outcome of 58 HCC treated patients who had achieved a complete response but later was referred to our institution’s multidisciplinary tumor board for a clinically suspected hidden HCC recurrence based on elevated tumor marker levels but negative gadoxetic acid-enhanced MRI. The imaging studies, tumor markers, and clinical information were reviewed. The total follow-up period was at least 15 months after the initial negative gadoxetic acid-enhanced MRI. Results Follow-up imaging studies detected an HCC lesion in 89.7% (n = 52/58) of the patients within the study period, and approximately half of the tumors (46.2%, n = 24/52) developed within 3 months. The most frequent site of recurrence was the liver (86.5%; n = 45/52), but extra-hepatic metastasis was also common (19.2%; n = 10/52). In 5.8% (n = 3/52), HCC reoccurred in the combined form of intra-hepatic and extra-hepatic recurrence. Extra-hepatic metastasis alone occurred in 13.5% (n = 7/52) of patients. Conclusions HCC frequently recurred within a short interval in patients who achieved a complete response to treatment in the presence of increased tumor marker levels, even if gadoxetic acid-enhanced MRI was negative. Under such circumstances, we suggest a short-term follow-up including, but not limited to, gadoxetic acid-enhanced MRI along with systemic evaluation.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Besa, Cecilia, Suguru Kakite, Nancy Cooper, Marcelo Facciuto et Bachir Taouli. « Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection : prospective crossover study at 3 T ». Acta Radiologica Open 4, no 2 (1 février 2015) : 204798161456128. http://dx.doi.org/10.1177/2047981614561285.

Texte intégral
Résumé :
Background Gadoxetic acid and gadopentetate dimeglumine are gadolinium-based contrast agents (GBCAs) with an established role in HCC detection and characterization. Purpose To compare gadopentetate dimeglumine and gadoxetic acid-enhanced magnetic resonance imaging (MRI) for image quality and hepatocellular carcinoma (HCC) detection/conspicuity. Material and Methods In this IRB approved cross-over pilot prospective study, 12 patients (all men; mean age, 56 years) with chronic liver disease at risk of HCC underwent two repeat MRI examinations using gadopentetate dimeglumine and gadoxetic acid (mean interval between studies, 5 days). Two independent observers analyzed images for image quality and HCC detection/conspicuity. Per-lesion sensitivity, positive predictive value, quantitative enhancement, and lesion-to-liver contrast ratio were calculated for both contrast agents. Results There was no significant difference in image quality scores between both GBCAs ( P = 0.3). A total of 20 HCCs were identified with reference standard in 12 patients (mean size 2.6 cm, range, 1.0–5.0 cm). Higher sensitivity was seen for observer 1 for gadoxetic acid-set in comparison with gadopentetate dimeglumine-set (sensitivity increased from 85.7% to 92.8%), while no difference was noted for observer 2 (sensitivity of 78.5%). Lesion conspicuity was significantly higher on hepatobiliary phase (HBP) images compared to arterial phase images with both GBCAs for both observers ( P < 0.05). Lesion-to-liver contrast ratios were significantly higher for HBP compared to all dynamic phases for both agents ( P < 0.05). Conclusion Our initial experience suggests that gadoxetic acid-set was superior to gadopentetate dimeglumine-set in terms of HCC detection for one observer, with improved lesion conspicuity and liver-to-lesion contrast on HBP images.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Lomovtseva, Karina K., et G. G. Karmazanovsky. « The possibility of applying magnetic resonance imaging with hepatospecific contrast agent. » Clinical Medicine (Russian Journal) 96, no 3 (20 juillet 2018) : 213–21. http://dx.doi.org/10.18821/0023-2149-2018-96-3-213-221.

Texte intégral
Résumé :
Nowadays, it is difficult to overestimate the role of cross-sectional imaging in the diagnosis of focal and diffuse liver diseases. In magnetic resonance imaging (MRI) there is a unique opportunity to use hepatospecific contrast agents compared with other visualization techniques. Gadoxetic acid is a hepatospecific magnetic resonance contrast agent which has the extracellular contrast agent properties and hepatotropic property. About half of the administered dose of gadoxetic acid enters into functioning hepatocytes through cell membrane transporters and then is excreted into the bile ducts and sinusoidal space. The obtained hepatobiliary phase provides information about the structural features of the focal liver lesions, improving their detection and differential diagnosis. In addition it allows to assess the anatomical and functional conditions of the hepatobiliary system. This article describes clinical applications of MRI with gadoxetic acid and its benefits, visualization principles of different focal liver lesions in hepatobiliary phase and features of the obtained images.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Ribeiro, Bruno Jucá, Aldo Maurici Araújo Alves, Rafael Santiago de Oliveira, Fernanda Velloni et Giuseppe D’Ippolito. « The role of gadoxetic acid-enhanced magnetic resonance cholangiography in the evaluation of postoperative bile duct injury : pictorial essay ». Radiologia Brasileira 52, no 6 (décembre 2019) : 403–7. http://dx.doi.org/10.1590/0100-3984.2018.0089.

Texte intégral
Résumé :
Abstract Iatrogenic lesion of the bile ducts is a relatively common occurrence during liver surgery, increasing morbidity and mortality rates. T2-weighted magnetic resonance cholangiography and gadoxetic acid-enhanced functional magnetic resonance cholangiography (fMRC) with administration of hepatobiliary-specific contrast medium (gadoxetic acid) are fundamental to the diagnostic imaging approach in patients with such lesions. Here, we present a review of the literature and suggest an imaging approach to biliary tract injury, focusing on clinical cases in which fMRC had an impact on the decision-making process for the management of the affected patients.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Renzulli, Matteo, Alfredo Clemente, Anna Maria Ierardi, Irene Pettinari, Francesco Tovoli, Stefano Brocchi, Giuliano Peta, Salvatore Cappabianca, Gianpaolo Carrafiello et Rita Golfieri. « Imaging of Colorectal Liver Metastases : New Developments and Pending Issues ». Cancers 12, no 1 (8 janvier 2020) : 151. http://dx.doi.org/10.3390/cancers12010151.

Texte intégral
Résumé :
Computed tomography (CT), magnetic resonance imaging (MRI), and 18-fluorideoxyglucose positron emission tomography (18FDG-PET) are historically the most accurate imaging techniques for diagnosing liver metastases. Recently, the combination of diffusion-weighted imaging and hepatospecific contrast media, such as gadoxetic acid in MRI, have been demonstrated to have the highest diagnostic accuracy, sensitivity, and specificity for detecting liver metastases. Various recent meta-analyses have confirmed the diagnostic superiority of this combination (diffusion-weighted imaging and gadoxetic acid-enhanced MRI), especially in terms of per lesion sensitivity, as compared with CT and 18FDG-PET, even for smaller lesions (≤1 cm). However, none of the oncological guidelines have suggested the use of MRI as a first-line technique for liver metastasis detection during the staging process of oncological patients. This review analyzes the history of the principal imaging techniques for the diagnosis of liver metastases, in particular of colorectal liver metastases, focusing on the most accurate method (diffusion-weighted imaging combined with gadoxetic acid-enhanced MRI), possible reasons for the lack of its diffusion in the guidelines, and possible future scenarios.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Acido Gadoxetico"

1

Lu, Yi Cheng. « Classifying Liver Fibrosis Stage Using Gadoxetic Acid-Enhanced MR Images ». Thesis, Linköpings universitet, Institutionen för medicin och hälsa, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-162989.

Texte intégral
Résumé :
The purpose is trying to classify the Liver Fibrosis stage using Gadoxetic Acid-EnhancedMR Images.  In the very beginning, a method proposed by one Korean group is being examined and trying to reproduce their result. However, the performance is not as impressive as theirs. Then, some gray-scale image feature extraction methods are used. Last but not least, the hottest method in recent years - ConvolutionNeural Network(CNN) was utilized. Finally, the performance has been evaluated in both methods. The result shows that with manual feature extraction, the Adaboost model works pretty well that AUC achieves 0.9. Besides, the AUC of ResNet-18 network - a deep learning architecture, can reach 0.93. Also, all the hyperparameters and training settings used on ResNet-18 can be transferred to ResNet-50/ResNet-101/InceptionV3 very well. The best model that can be obtained is ResNet-101which has an AUC of 0.96 - higher than all current publications for machine learning methods for staging liver fibrosis.
Styles APA, Harvard, Vancouver, ISO, etc.
2

PRADELLA, SILVIA. « Effects of age and Gadoxetic Acid on quantitative DW Imaging of the liver ». Doctoral thesis, 2013. http://hdl.handle.net/2158/800876.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Elbakkoush, Abdallah Ahmed, et 艾伯樺. « Hepatobiliary transit times of Gadoxetic Acid in Magnetic Resonance Imaging of patients with liver cirrhosis ». Thesis, 2014. http://ndltd.ncl.edu.tw/handle/75963994034199480462.

Texte intégral
Résumé :
碩士
國立陽明大學
生物醫學影像暨放射科學系
102
Background and Objective: Chronic liver disease and cirrhosis result in about 35,000 deaths each year in the United States. Cirrhosis is the ninth leading cause of death in the United States and is responsible for 1.2% of all US deaths. MRI has been reported to be an excellent imaging modality because of its high tissue contrast and use of tissue-specific contrast agents. Gadoxetic acid (Gd-EOB-DTPA) is a more recently developed liver specific MR imaging contrast agent. The excretion of Gd-EOB-DTPA might be related to the liver disease and liver function. The pur¬pose of this study was to determine transit times for excretion of Gd-EOB-DTPA in the hepatobiliary system in patients with liver cirrhosis1. Material and Methods: Institutional Review Board of our hospital approved the study; in-formed consent was waived. We retrospectively included consecutive patients with liver cirrho¬sis who underwent contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2012. Finally, the 47 patients were en-rolled in this study. The Gd-EOB-DTPA-enhanced MRI included arterial phase (18~20sec, arterial phase, AP), por¬tal venous phase (50~55 sec, portal venous phase, PP), venous phase (85~90s, venous phase, VP) and three delayed phases (180s, 20mins and 30mins after the injection of contrast agent). The images were evaluated for the presence of contrast agent in the intra-hepatic bile ducts (IHD), the common bile duct (CBD), the gallbladder and the duodenum in AP, PP, VP and three delay phases. Results: The optimal time of arterial phase was from 15 s after injection, and the optimal time for portal venous imaging was from 40 s after injection. Meanwhile, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (39/47, 83 %) at the IHD and 37 patients (37/47, 78.5%) at the CBD. Gallbladder reflux was visible in 26 (26/47, 43%), duodenal excretion in 17 patients (17/47, 36%), respectively. After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (6/47, 13 %) at the IHD and 7 patients (7/47, 15 %) at the CBD, and gallbladder reflux was visible in 10 (10/47, 21%), duodenal excretion in 20 patients (26/47, 55%), respectively.(Fig 2 and Fig 3) GB was not visible in 9 patients, 4 out of these 9 patients received cholecystectomy. Conclusion: The results of our study shows that in patients with liver cirrhosis, the excretion of Gd-EOB-DTPA can be observed. Our results also demonstrated that the bilirubin level and the severity of cirrhosis (according to the Child Pugh scores had certain effect on excretion of Gd-EOB-DTPA into biliary tree.
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Acido Gadoxetico"

1

Mandorfer, M., N. Bastati, L. Beer, S. Pötter-Lang, D. Tamandl, B. Yesim, MC Elmer et al. « Functional Liver Imaging Score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with chronic liver disease ». Dans 52. Jahrestagung & 30. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1691858.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Wei, Jingwei, Dongsheng Gu, Di Dong, Shuaitong Zhang, Yushen Jin et Jie Tian. « Abstract 1294 : Preoperative prediction of microvascular invasion in HCC using radiomics on multisequence gadoxetic acid-enhanced MR images ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1294.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Mandorfer, M., L. Haider, Z. Güngören, T. Reiberger, N. Bastati, JC Hodge, D. Chromy et al. « Gadoxetic acid enhanced MRI distinguishes advanced chronic liver disease patients with improving liver function after sustained virologic response and patients with persistent liver damage ». Dans 51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1654647.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Acido Gadoxetico » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie